Viewing data from:

CRESEMBA

NDA

ISAVUCONAZONIUM SULFATE | N207500 | ASTELLAS PHARMA US INC

2 strengths3 unique patents9 unique exclusivities

Patent Timeline

3 unique patents, 7 exclusivities by expiration date

Expired (1)Active (2)TodayPED (+6 mo)Exclusivity

2022

2023

2024

2025

2026

2027

2028

2029

2030

2031

Today

6812238

Apr. 30, 2026

10206879

Mar. 14, 2028

10603280

Mar. 14, 2028

ODE-305

Jun. 8, 2031

ODE-90

Jun. 8, 2031

ODE*

Jun. 8, 2031

NPP

Jun. 8, 2031

GAIN

Jun. 8, 2031

ODE-454

Jun. 8, 2031

ODE-458

Jun. 8, 2031

PTAB Proceedings

No IPR/PGR/CBM challenges found at the Patent Trial and Appeal Board

Patent Reexaminations

No ex parte or inter partes reexamination proceedings found at USPTO

Hatch-Waxman Litigation

Para IV certification filed but no ANDA patent litigation cases (NOS 835) matched from PACER. Litigation may be pending or filed under a different caption.

Citizen Petitions

No FDA citizen petitions matched from Regulations.gov

Clinical Trials

No clinical trials found on ClinicalTrials.gov for this drug

Medicare Part D Spending

CMS annual spending data for Cresemba* (2023)

Total Spending

$95.7M

Total Claims

14,677

Beneficiaries

3,570

Avg Cost/Unit

$110.15

Spending Trend

$41.9M(2019)→$55.6M(2020)→$59.9M(2021)→$72.6M(2022)→$95.7M(2023)

YoY Change:+8.3%

5yr CAGR:+3.5%

Source: CMS Medicare Part D Spending by Drug (2023). Shows gross drug cost under Part D.

API Supply Chain15 active DMFs

14 active API suppliers hold Drug Master Files for this ingredient.

METROCHEM API PRIVATE LTDISAVUCONAZONIUM SULFATE

DMF 369742022

ALIVUS LIFE SCIENCES LTDISAVUCONAZONIUM SULFATE

DMF 382512023

BRIGHTGENE BIO-MEDICAL TECHNOLOGY CO LTDISAVUCONAZONIUM SULFATE

DMF 385022023

BIOPHORE INDIA PHARMACEUTICALS PVT LTDISAVUCONAZONIUM SULFATE

DMF 387812023

HONOUR LAB LTDISAVUCONAZONIUM SULFATE

DMF 387842023

ZAKLADY FARMACEUTYCZNE POLPHARMA SAISAVUCONAZONIUM SULFATE

DMF 389642023

PORTON PHARMA SOLUTIONS LTDISAVUCONAZONIUM SULFATE API, NON-STERILE DRUG SUBSTANCE

DMF 390122023

CIPLA LTDISAVUCONAZONIUM SULFATE

DMF 391512023

SICHUAN D-INNOVATION PHARMACEUTICAL CO LTDISAVUCONAZONIUM SULFATE

DMF 391932023

MSN LIFE SCIENCES PRIVATE LTDISAVUCONAZONIUM SULFATE

DMF 394962024

OPTIMUS DRUGS PRIVATE LTDISAVUCONAZONIUM SULFATE

DMF 397772024

METROCHEM API PRIVATE LTDISAVUCONAZONIUM SULFATE (KYO)

DMF 398232024

SHANGHAI DESANO CHEMICAL PHARMACEUTICAL CO LTDISAVUCONAZONIUM SULFATE

DMF 403242024

BEIJING HOPE PHARMACEUTICAL CO LTDISAVUCONAZONIUM SULFATE

DMF 407732024

GLAND PHARMA LTDISAVUCONAZONIUM SULFATE

DMF 418872025

Source: FDA Drug Master Files (fda.gov). Type II API DMFs matched by ingredient.

Approval Letters

9 letters from Drugs@FDA

Date	Submission	Document
Mar 25, 2025	SUPPL -16	View Letter (PDF)
Dec 11, 2023	SUPPL -15	View Letter (PDF)
May 4, 2022	SUPPL -11	View Letter (PDF)
Dec 14, 2021	SUPPL -10	View Letter (PDF)
May 19, 2021	SUPPL -6	View Letter (PDF)
Apr 26, 2021	SUPPL -8	View Letter (PDF)
Dec 11, 2019	SUPPL -5	View Letter (PDF)
Apr 6, 2015	SUPPL -1	View Letter (PDF)
Mar 6, 2015	ORIG -1	View Letter (PDF)

Source: Drugs@FDA application documents.

Products (2)

Sort:

#001 — 186MG

RLD

3 patents7 exclusivities▴

CAPSULE;ORAL | Approved: Mar 6, 2015

Patents (3)

Patent #	Expiration	PED	Drug Substance	Drug Product	Use Code	Delist
6812238	Oct 31, 2025PED: Apr 30, 2026	PED	Yes	—	—	—
10206879	Sep 14, 2027PED: Mar 14, 2028	PED	—	Yes	—	—
10603280	Sep 14, 2027PED: Mar 14, 2028	PED	—	Yes	—	—

Exclusivities (7)

Code	Date	Status
GAIN	Sep 6, 2027	Active
NPP	Dec 8, 2026	< 1 year
ODE-305	Mar 6, 2022	Expired
ODE-454	Dec 8, 2030	Active
ODE-458	Dec 8, 2030	Active
ODE-90	Mar 6, 2022	Expired
PED	Sep 6, 2022	Expired

#002 — 74.5MG

RLD

3 patents6 exclusivities▾

CAPSULE;ORAL | Approved: Nov 22, 2022